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Five human hepatitis viruses cause most of the acute and chronic liver disease worldwide. Over the past 25
years, hepatitis C virus (HCV) in particular has received much interest because of its ability to persist in most
immunocompetent adults and because of the lack of a protective vaccine. Herewe examine innate and adap-
tive immune responses to HCV infection. Although HCV activates an innate immune response, it employs an
elaborate set of mechanisms to evade interferon (IFN)-based antiviral immunity. By comparing innate and
adaptive immune responses to HCVwith those to hepatitis A and B viruses, we suggest that prolonged innate
immune activation by HCV impairs the development of successful adaptive immune responses. Comparative
immunology provides insights into the maintenance of immune protection. We conclude by discussing
prospects for an HCV vaccine and future research needs for the hepatitis viruses.Introduction
Although epidemics of jaundice, most likely caused by viral hep-
atitis, date back thousands of years to ancient China (Fonseca,
2010), the five viruses (named hepatitis A to E viruses) that are
responsible for the majority of the world’s cases of acute and
chronic hepatitis were discovered only in the past 60 years
(Table 1). Combined, they cause a wide spectrum of disease
ranging from inapparent to fulminant hepatitis in acute infection
and from mild necroinflammatory liver disease to cirrhosis and
hepatocellular carcinoma in chronic infection. They are also
responsible for the majority of liver transplantations worldwide.
Hepatitis B virus (HBV), the first such described virus, is
responsible for about 350 million chronic infections worldwide,
mostly resulting from vertical transmission from mother to child
(Chisari et al., 2010). HBV is a small, enveloped DNA virus that
establishes a minigenome, the covalently closed circular DNA
(cccDNA), as its transcriptional template in host cells (Levrero
et al., 2009). In contrast to infection early in life, infection during
adulthood usually results in acute self-resolving hepatitis and
protective immunity (Chisari et al., 2010). Hepatitis D virus
(HDV) is an enveloped, negative sense, single-stranded, closed
circular RNA virus. HDV requires HBV to propagate, and infec-
tion with both viruses typically results in severe liver pathology
(Taylor, 2012). Hepatitis A virus (HAV) and hepatitis E virus
(HEV) are positive-stranded nonenveloped RNA viruses trans-
mitted via the fecal-oral route and typically cleared after acute
infection of immunocompetent individuals. A high incidence of
severe HAV infections is observed among nonvaccinated per-
sons who encounter the infection late in life andmany HEV infec-
tions are fatal in pregnant women (Hoofnagle et al., 2012; Qu and
Lemon, 2010). Hepatitis C virus (HCV) is also a positive-stranded
RNA virus, but it is parenterally transmitted and establishes a
high percentage of chronic infections upon transmission be-
tween adults. About 170 million people worldwide are infected
and at risk of developing liver cirrhosis and hepatocellular carci-
noma (Rehermann, 2009). Although great progress has been
made in the development of antiviral therapies for HCV (Heim,
2013; Scheel and Rice, 2013), HCV remains the sole hepatitis
virus for which a vaccine is not yet available. A complicating fac-
tor for the development of an HCV vaccine is the absence of anti-body-based sterilizing immunity against reinfection (Liang,
2013).
This review describes our current knowledge of innate and
adaptive immune responses to HCV. Studies of HCV’s elaborate
mechanisms to prevent and counteract the host innate and
adaptive immune responses have yielded many discoveries
that range from genetic variants affecting spontaneous and
interferon-a (IFN-a)-based viral clearance to pathways of IFN
and interferon-stimulated gene (ISG) induction and evasion,
sensing of viral RNA by noninfected nonparenchymal cells, and
conditions for success and failure of adaptive immune re-
sponses and protective immunity. Comparative aspects of
HAV and HBV immunology are highlighted because they provide
unique insights into the link between innate and adaptive
responses and the maintenance of immune memory. The latter
may be relevant for the development of a prophylactic T cell-
based vaccine against HCV. Future research needs for hepatitis
A, B, and C virus infection and the immunologically barely
studied hepatitis D and E virus infections are described at the
end of the review.
Innate Immune Responses to HCV
Many patients are diagnosed with HCV infection after decades
of chronic hepatitis. Despite high viral titers, HCV proteins are
expressed at such low amounts that immunohistochemistry is
not adequate to assess the proportion of infected hepatocytes.
Advanced techniques such as 2-photon microscopy (Liang
et al., 2009) and in situ hybridization with large sets of HCV
isolate-specific probes (Wieland et al., 2013) estimate that up to
30%–50% of hepatocytes are infected in patients with chronic
hepatitis C. Hepatocytes are infected by blood-borne HCV
through a complex series of events that includes binding of the vi-
rus to several low-affinity attachment receptors in addition to the
tetraspanin CD81, the scavenger receptor class B type I (SR-B1),
the tight junction proteins occludin (OCLN) and claudin (CLDN1),
and the cholesterol absorption receptor Niemann-Pick C1-like 1
(NPC1L1) (Lindenbach and Rice, 2013). In addition, cell-to-cell
transmission of infectivity has been demonstrated in hepatoma
cell cultures in the presence of neutralizing antibodies (Ramak-
rishnaiah et al., 2013; Timpe et al., 2008). This is consistent withImmunity 40, January 16, 2014 ª2014 Elsevier Inc. 13
Table 1. The Hepatitis Viruses
HAV HBV HCV HDV HEV
Discovery (year) 1973 1965 (HBsAg) 1989 1977 (Delta antigen) 1983 (virus particle)
1970 (HBV particle) 1986 (HDV cloned) 1990 (HEV cloned)
Genome +ssRNA partially dsDNA +ssRNA ssRNA +ssRNA
Virus structure 28 nm; nonenveloped
nucleocapsid
42 nm; enveloped nucleocapsid 50 nm; enveloped nucleocapsid 40 nm; enveloped nucleocapsid 27–34 nm; nonenveloped
nucleocapsid
Classification Hepatovirus genus;
Picornaviridae family
Orthohepadnavirus genus;
Hepadnaviridae family
Hepacivirus genus; Flaviviridae
family
Deltavirus genus Hepevirus genus;
Hepeviridae family
Genotype 3 major genotypes;
6 subtypes
8 genotypes (8% intergroup
divergence)
6 major genotypes; more than
50 subtypes; quasispecies in
each infected patient
8 genotypes 4 genotypes; 24 subtypes
Mutation rate high (1/1,000–1/6,000
bases/year)
low (1/100,000 bases/year) high (1/1,000 bases/year) high (1/300–1/3,000 bases/year) high (1/700 bases/year)
Viral half-life time unknown 2–3 days 3 hr unknown unknown
Virion production unknown 1010–1012 virions/day 1012 virions/day unknown unknown
Worldwide prevalence 1.5 million people 350 million people 170 million people 20 million people 14 million people
Transmission enteral, fecal-oral parenteral parenteral parenteral enteral, fecal-oral; infrequent:
parenteral
Disease outcome acute, self-limited mostly acute, self-limited if infection
occurs during adulthood; mostly
chronic after neonatal infection
acute, 60%–80% develop chronic
infection
depends on HBV infection; 2% of
HBV/HDV coinfections and 90%
of HDV superinfections persist
acute, self-limited; chronic
infection mainly in
immunocompromised
patients
15%–25% of patients with chronic
hepatitis B die from liver failure or
liver carcinoma
1%–5% of patients with chronic
hepatitis C die from liver failure
or liver carcinoma
70%–80% of patients with chronic
hepatitis D develop cirrhosis; 60%
of these die within 10 years
57,000 death/year in
worldwide
Vaccine yes (inactivated or
live attenuated);
vaccination prevents
infection for more than
25 years
yes (recombinant HBsAg);
vaccination of neonates prevents
persistent infection
no (not available) vaccine against HBV protects
against HDV infection
yes (approved in China)
Treatment of
persistent infection
not applicable IFN-a-based therapy achieves
seroconversion in a minority of
patients; nucleos(t)ide analogs
suppress but do not eradication
of HBV
pegylated IFN-a, ribavirin, direct
acting antivirals; HCV clearance
in 45%–80% of individuals
depending on HCV genotype
high doses of IFN-a-based therapy
effective in only about 20% of
patients; HDV relapses in most
cases after cessation of treatment
not applicable
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Figure 1. HCV Induces and Evades Innate Immune Responses in the Liver
(A) HCV-infected hepatocytes form clusters (indicated in green) in the infected liver (Wieland et al., 2013), consistent with the cell-to-cell transmission observed in
hepatoma cultures (Ramakrishnaiah et al., 2013; Timpe et al., 2008).
(B) Specific HCV RNA structures are recognized by PKR, RIG-I, and TLR3 in cell culture experiments. PKR and RIG-I signals are transmitted via MAVS, and TLR3
signals are transmitted via TRIF. Downstream activation of kinases, IRF-3-dependent induction of IFN-b, and NF-kB-dependent induction of proinflammatory
cytokines such as TNF-a and CXCL10 is abrogated in the presence of HCV NS3-4A, which cleaves both MAVS (Foy et al., 2003) and TRIF (Li et al., 2005). The
induction of IFNL1 transcription is indicated by a dotted line because this pathway has been demonstrated in other models (Osterlund et al., 2007) and not yet
been confirmed for HCV infection. The secreted interferons bind to their respective receptors, which via activation of the Jak-STAT pathway amplifies the IFN
response and induces a large set of ISGs (not shown). Abbreviations are as follows: IRES, internal ribosomal entry site; dsRNA, double-stranded RNA; PKR, RNA-
dependent protein kinase R; RIG-I, retinoic acid-inducible gene 1; TLR3, toll-like receptor 3; MAM, mitochondria-associated endoplasmic reticulum membrane;
MAVS, mitochondrial antiviral signaling protein; TBK1, TANK-binding kinase 1; TRIF, Toll/IL-1 receptor domain-containing adaptor inducing IFN-b; IRF-3, IFN-
regulatory factor 3.
(C) HCV persists in the presence of ISGs. IFN-b production is blocked in the upper right hepatocytes because of intracellular expression of HCVNS3-4A.Whether
individual hepatocytes transiently express IFN-b and potentially IFN-l1 in response to HCVRNA, e.g., in the context of an abortive intracellular infection or prior to
accumulating sufficient NS3-4A as indicated in the upper left hepatocyte, is not known at present. Nonparenchymal cells, e.g., Kupffer cells, pDCs, and BDCA3+
mDC2s may contribute to the production of ISG-inducing IFNs. The induced IFNs bind to their respective receptors, activate the Jak-STAT pathway, and induce
ISG mRNA and proteins in HCV-uninfected hepatocytes (lower part of the figure). Although ISG mRNAs are induced in HCV-infected hepatocytes (indicated in
green), HCV may persist by phosphorylating and activating PKR. PKR blocks cap-dependent translation of host proteins but not IRES-dependent translation of
HCV proteins (see text for details). Continuous exposure to IFN-a increases STAT1 expression in NK cells and results in increased pSTAT1-dependent cyto-
toxicity (CD107a expression and TRAIL production) and decreased pSTAT4-dependent IFN-g production (see text for details). Abbreviations are as follows: KC,
Kupffer cell; pDC, plasmacytoid dendritic cell; mDC2, myeloid dendritic cell; NK, natural killer cell; TRAIL, tumor necrosis factor-related apoptosis-inducing
ligand.
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Reviewthe finding that HCV-infected hepatocytes are arranged in clus-
ters in the infected liver (Figure 1A; Wieland et al., 2013).
In infected hepatocytes, the HCV RNA genome is translated
into a single protein that is cotranslationally and posttransla-
tionally processed by cellular and viral proteases into structural
(C, E1, E2, p7) and nonstructural (NS2–NS5B) proteins. The
nonstructural proteins become a part of a perinuclear mem-brane-associated replication complex in which progeny posi-
tive-strand RNA molecules are transcribed via negative-strand
RNA intermediates (Lindenbach and Rice, 2013).
Analysis of the full HCV life cycle became possible only in 2005
when the highly replicative HCV JFH-1 strain was cloned and
used to establish infection in human hepatoma cells (Lindenbach
et al., 2006; Wakita et al., 2005; Zhong et al., 2005). OtherImmunity 40, January 16, 2014 ª2014 Elsevier Inc. 15
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Reviewsystems to dissect intracellular innate immune responses
include hepatoma cells transfected with HCV RNA or subge-
nomic HCV replicons (Lohmann and Bartenschlager, 2013). In
these models, several HCV RNA structures are recognized by
cytosolic pattern recognition receptors (Figure 1B). The HCV
internal ribosomal entry site (IRES) is recognized by RNA-depen-
dent protein kinase R (PKR) whereas RIG-I seems to be impor-
tant for recognition of the HCV 30 poly-U/UC sequence, the 50 tri-
phospate of the uncappedHCVRNA, and short double-stranded
RNA regions (reviewed in Horner and Gale, 2013). Longer dou-
ble-stranded HCV RNA intermediates activate endosomal toll-
like receptor 3 (TLR3) but in infected hepatoma cells that ectop-
ically express this receptor, this occurs after viral recognition by
PKR and RIG-I (Li et al., 2012; Wang et al., 2009). Upon activa-
tion, PKR and RIG-I signals are transmitted via mitochondrial
antiviral signaling protein (MAVS, also called VISA, IPS-1, and
CARDIF), whereas TLR3 signals are transmitted via the adaptor
molecule Toll/IL-1 receptor domain-containing adaptor inducing
IFN-b (TRIF) (reviewed in Horner and Gale, 2013). These
signaling cascades can lead to the synthesis of IFN-b via activa-
tion of TANK-binding kinase 1 (TBK1) and phosphorylation,
dimerization, and nuclear translocation of IFN-regulatory factor
3 (IRF-3). In addition, synthesis of proinflammatory cytokines
such as TNF-a and CXCL10 can result from activation of the ca-
nonical IkB kinase complex and nuclear translocation of NF-kB.
However, HCV escapes from such innate responses by NS3-4A
serine protease-mediated cleavage of MAVS (Foy et al., 2003)
and TRIF (Li et al., 2005), which blocks IFN-b and ISG induction
in infected hepatoma cells (Cheng et al., 2006). This is supported
by translational studies that demonstrate the presence of
cleavedMAVS in the liver biopsies of HCV- but not HBV-infected
patients (Bellecave et al., 2010). MAVS cleavage is specifically
detected in HCV NS3-expressing hepatocytes (Loo et al.,
2006) along with the cytoplasmic (i.e., inactive) form of IRF-3
(Lau et al., 2008). Whether IFN production is completely blocked
in HCV-infected hepatocytes or whether individual hepatocytes
transiently express type I and III IFNs in situ in response to
HCVRNA, e.g., in the context of an abortive intracellular infection
or prior to accumulating sufficient NS3-4A (Figure 1C), is un-
known.
It is established, however, that noninfected nonparenchymal
cells are an alternative source of type I and III IFNs during HCV
infection (Figure 1C). Kupffer cells, the dominant macrophage
population in the liver sinusoids, express IFN-b protein in liver bi-
opsies of HCV-infected patients (Lau et al., 2013). This is consis-
tent with the induction of IFN-b in a human macrophage cell line
after in vitro exposure to HCV (Lau et al., 2013). Phagocytic up-
take of HCV RNA also triggers an inflammatory IL-1b response
via TLR7-mediated inflammasome activation in these cells (Neg-
ash et al., 2013). Plasmacytoid dendritic cells (pDCs) constitute a
second nonparenchymal cell population that may contribute to
the intrahepatic IFN response. Although pDC cultures do not
respond directly to HCV (Shiina and Rehermann, 2008), they
have been shown to take up HCV RNA via exosomes from hep-
atoma cells that harbor subgenomic HCV replicons (Takahashi
et al., 2010). This process requires direct cell-to-cell contact
and results in the activation of TLR7 within endosomes and in
production of IFN-a by pDCs (Dreux et al., 2012). However,
this mechanism still needs to be confirmed in the infected liver.16 Immunity 40, January 16, 2014 ª2014 Elsevier Inc.Finally, IFN-ls may contribute to ISG induction. IFN-l1 in
particular has been detected at high concentrations in sera of
chimpanzees with acute HCV infection (Park et al., 2012a) and
in patients with chronic HCV infection (Thomas et al., 2012).
Similar to IFN-a and IFN-b, IFN-ls can be produced by nonpar-
enchymal cells and thereby bypass an HCV-induced attenuation
of type I IFN production in HCV-infected hepatocytes. For
example, in coculture experiments, human BDCA3+ myeloid
DCs (mDC2s), which are rare in the circulation but enriched in
the liver, recognize HCV-infected hepatoma cells in a TLR3-
and TRIF-mediated manner and produce IFN-ls (Figure 1C;
Zhang et al., 2013). Thus, it is conceivable that IFN-a, IFN-b,
and IFN-l production by nonparenchymal cells contribute to
ISG induction in the HCV-infected liver by stimulating the
receptor for IFN-a and IFN-b and the receptor for IFN-l and
the downstream Jak-STAT pathway in hepatocytes. The com-
plete characterization of induced the ISGs and their antiviral ef-
fect and mechanism of action is an area of intense investigation
(Metz et al., 2013; Schoggins et al., 2011).
How does HCV persist in the presence of high ISG expres-
sion? Based on experiments with overexpressed HCV proteins,
in either transfected cells or transgenic mice (reviewed in Reher-
mann, 2009), interference with Jak-STAT signaling was initially
proposed as an HCV escape strategy. However, Jak-STAT
signaling is not impaired in HCV-infected cells with lower, sup-
posedly more physiologic, amounts of HCV proteins (Cheng
et al., 2006). Furthermore, HCV RNA and ISGmRNA are simulta-
neously detected in hepatocytes of patients with chronic HCV
infection (Wieland et al., 2013). A possible alternative explanation
is a posttranscriptional block in ISG expression resulting from
HCV-induced phosphorylation of PKR. PKR is an ISG that in-
hibits the elongation initiation factor 2a and thereby decreases
the cap-dependent translation of cellular mRNAs as shown in
HCV-infected hepatoma cells (Garaigorta and Chisari, 2009).
Translation of HCV proteins is less affected in this setting
because it occurs in an IRES-dependent manner (Figure 1C;
Garaigorta and Chisari, 2009). Finally, HCV may interfere
directly with the function of individual ISGs (Figure 1C), but the
complexity and redundancy of the ISG system would require
an arsenal of target-specific interference strategies. Collectively,
these findings suggest that clusters of HCV-infected hepato-
cytes are surrounded by rings of noninfected hepatocytes that
express antiviral proteins encoded by ISGs. Advanced imaging
techniques may be used to examine whether such structures
are locked in place or whether they move through the liver,
perhaps influenced by the differentiation status of individual
hepatocytes or regeneration of the liver itself.
Chronic Innate Immune Activation Negatively Predicts
the Response to IFN-a-Based Therapy
Continued ISG expression in the chronically HCV-infected liver
has both clinical and immunological consequences. It is the
strongest negative predictor of a response to IFN-a-based ther-
apy, the standard treatment for the past 25 years (Heim, 2013).
High intrahepatic ISG expression prior to therapy is associated
with a minor increase in expression during IFN-a-based therapy
and lack of a virological response (Dill et al., 2011). Likewise,
the amount of nuclear pSTAT1 prior to treatment is higher in he-
patocytes of nonresponders to IFN-a-based therapy than in
Immunity
Reviewthose of responders, which suggests that the preactivated IFN
response is refractory to further stimulation (Sarasin-Filipowicz
et al., 2008). This correlation extends to innate immune cells
that respond to IFN-a. NK cells of patients with chronic HCV
infection display higher amounts of STAT1 than do those of
healthy controls (Miyagi et al., 2010). This is accompanied by
increased NK cell cytotoxicity and decreased IFN-g production
(Ahlenstiel et al., 2010; Oliviero et al., 2009). Based on a mecha-
nism first described in mice infected with lymphocytic choriome-
ningitis virus (LCMV), this reflects an IFN-a signature because
increased STAT1 expression results in preferential phosphoryla-
tion of STAT1 over STAT4 and an increase in pSTAT1-dependent
NK cell cytotoxicity over pSTAT4-dependent IFN-g production
(Miyagi et al., 2007). The continued IFN-a-mediated stimulation
of NK cell cytotoxicity in the absence of viral clearance may fulfill
an immunoregulatory role rather than antiviral role as discussed
in a recent review (Rehermann, 2013). Consistent with what has
been reported for intrahepatic ISG expression, there is a nega-
tive correlation between the pretreatment activation status of
NK cells and the relative increase in their activation status during
IFN-a-based therapy, which predicts the subsequent virological
treatment response (DeMaria et al., 2007). Furthermore, NK cells
from patients with rapid HCV RNA decline upon treatment initia-
tion exhibit maximal in vivo pSTAT1 induction in response to IFN-
a-based therapy, whereas NK cells of patients with slow HCV
RNA decline exhibit lower in vivo pSTAT1 induction (Edlich
et al., 2012). This is consistent with greater increase in NK cell
cytotoxicity during IFN-a-based therapy in treatment responders
than in nonresponders (Ahlenstiel et al., 2011).
Recently identified genetic variants on chromosome 19 within
or near the IFNL3 gene are also associated with spontaneous
and treatment-induced outcome of HCV infection and add to
the predictive value of pretreatment expression of ISGs (Ge
et al., 2009; Tanaka et al., 2009; Thomas et al., 2009). The favor-
able rs12979860 CC-variant, located 3 kb upstream of the IFNL3
gene, is more prevalent in Europeans and Asians than in African
Americans and therefore tracks with the differential treatment
response rates of these populations. However, the mecha-
nisms for the genetic basis of HCV clearance in the context
of rs12979860 and the related rs8103142, rs4803217, and
ss469415590 SNPs in the same haplotype block are not under-
stood. The rs8103142 SNP is located in the IFNL3 coding region
but does not change the functional properties of the IFNL3 pro-
tein (Urban et al., 2010). The rs4803217 SNP is located in the 30
untranslated region of the IFNL3, and its T-variant may decrease
the stability of the IFNL3mRNA via posttranscriptional regulation
by HCV-induced miRNAs based on in vitro experiments (McFar-
land et al., 2013). However, there is no consistent demonstration
that differential IFNL3 mRNA or IFN-l3 protein expression in
HCV-infected patients are associated with divergent outcomes
of HCV infection (Dill et al., 2011; Honda et al., 2010; Langhans
et al., 2011; Urban et al., 2010). The ss469415590 SNP is located
between IFNL3 and IFNL2 and improves the prediction of treat-
ment outcome for African Americans. ItsDG dinucleotide variant
creates an open-reading frame in IFNL4 (Prokunina-Olsson
et al., 2013). Overexpression of an IFN-l4 fusion protein induces
ISGs and antiviral activity in transfected hepatoma cells but an
infection-induced secreted protein has not yet been detected.
Thus, the mechanisms that explain the genetic determinants ofHCV clearance are not understood at present, and ISG expres-
sion remains an independent negative predictor of the response
to IFN-based therapy.
Adaptive Immune Responses to HCV
A unique feature of HCV infection is the late appearance of adap-
tive immune responses, which typically are detectable no earlier
than 8–12 weeks after infection in both self-limited (Figure 2A)
and chronically evolving (Figure 2B) hepatitis C. In the following
sections, we describe HCV-specific responses and compare
them to HAV- and HBV-specific responses, leading to the
hypothesis that prolonged ISG activation interferes with the
development of protective immunity.
The small percentage of patients who clear HCV typically
mount broad CD4+ T cell responses in the acute phase of HCV
infection with better T cell proliferation and IL-2, IFN-g, and
TNF-a production than patients who develop chronic infection
(Figure 2C; Diepolder et al., 1995; Missale et al., 1996; Smyk-
Pearson et al., 2008; Urbani et al., 2006). In particular, the
differential expansion of CD161hiCCR6+CD26+ CD4+ T cells
that express IL-17A and IL-21 along with Th17 cell lineage-spe-
cific transcription factors appears to correlate with the outcome
of infection (Kared et al., 2013). IL-17A plasma concentrations
are higher in the acute phase of hepatitis in patients with self-
limited infection than in patients with chronically evolving HCV
infection. This is followed by differential IL-21 concentration
several weeks later (Kared et al., 2013). If broadly directed
CD4+ T cell responses are detected in acutely infected patients
who later develop chronic hepatitis, these T cells undergo rapid
exhaustion with sequential loss of IL-2 production, proliferation,
and IFN-g production (Gerlach et al., 1999; Semmo et al., 2005)
and increased expression of the inhibitory receptors T cell immu-
noglobulin domain and mucin domain 3 (TIM-3), programmed
death 1 (PD-1), and cytotoxic T lymphocyte antigen 4 (CTLA-4)
(Raziorrouh et al., 2011). An expansion of galectin-9 (Gal-9)
expressing regulatory T (Treg) cells and increased Gal-9
plasma concentrations in these patients has been reported
(Kared et al., 2013), and it has been proposed that binding of
Gal-9 to Tim-3 inhibits IL-21-producing HCV-specific Th17 cells
(Figure 2C).
In contrast to CD4+ T cells, HCV-specific CD8+ T cells are typi-
cally ‘‘stunned’’ in all patients in the early acute phase of HCV
infection as evidenced by impaired proliferation, IFN-g produc-
tion, and cytotoxicity (Lechner et al., 2000; Thimme et al.,
2001; Urbani et al., 2006) and increased cell surface expression
of the PD-1 molecule (Figure 2C; Kasprowicz et al., 2008).
Initiation of IFN-a-based therapy in the acute infection results
in a rapid decay of CD8+ T cell responses (Rahman et al.,
2004), suggesting that most HCV-specific CD8+ T cells are short
lived, antigen-dependent effector cells rather than self-sustain-
ing memory T cells in this phase. However, PD-1 expression
on HCV-specific CD8+ T cells can be transient in acute hepatitis
C and, along with CD38 expression, can reflect CD8+ T cell
activation rather than exhaustion in this phase of the response
(Kasprowicz et al., 2008; Shin et al., 2013). If HCV infection is
self-limited, the HCV-specific CD8+ T cell population loses
expression of PD-1 and gains expression of the antiapoptotic
molecule Bcl-2 and the IL-7 receptor CD127 (Shin et al., 2013;
Thimme et al., 2001; Urbani et al., 2006). HCV-specific CD8+Immunity 40, January 16, 2014 ª2014 Elsevier Inc. 17
Figure 2. Clinical, Virological, and Immunological Course of Acute HCV Infection
(A) Acute hepatitis C followed by clinical recovery. The incubation phase with high viremia titer and ISG expression occurs during the first 8 weeks of infection. The
acute phase is marked by elevated alanine aminotransferase (ALT) levels and the onset of HCV-specific CD4+ and CD8+ T cell responses around weeks 8 to 12.
HCV-specific antibodies are detectable by enzyme immunoassay (ELISA) a fewweeks later, but the impact of low titers of strain-specific neutralizing antibodies is
still controversial. After spontaneous resolution of acute HCV infection, HCV-specific memory T cell responses remained detectable for decades whereas an-
tibodies disappear from the circulation.
(B) Acute hepatitis C followed by chronic infection. HCVRNA titers decrease 2–3 log10 after the acute phase of hepatitis C and remain relative stable in the chronic
phase. Selection of HCV escape mutants is mostly driven by T cells in the acute and early chronic phases of infection and by increasing titers of broadly targeted
neutralizing antibodies in the chronic phase. The intensity of the shaded background indicates the degree of intrahepatic inflammation in the different phases of
hepatitis.
(legend continued on next page)
18 Immunity 40, January 16, 2014 ª2014 Elsevier Inc.
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ReviewT cells are thought to contribute to HCV clearance because the
increase in CD8b and IFN-g mRNA expression in the liver coin-
cides with a 90%–99% decrease in viral titer in acutely infected
chimpanzees (Shin et al., 2006), and because depletion of either
CD4+ (Grakoui et al., 2003) or CD8+ (Shoukry et al., 2003) T cells
prevents HCV clearance in this model.
In patients with chronically evolving hepatitis, antigen-driven
exhaustion and loss of IL-21-producing Th17 cells are thought to
contribute to the failure to generate successful HCV-specific
CD8+ T cell responses (Kared et al., 2013). In vitro blockade of
Tim-3, PD-1, and CTLA-4 increases the frequency of IL-17A-
and IL-21-producing HCV-specific CD4+ T cells in cultures of
peripheral blood mononuclear cells that are obtained during the
acute phase of infection (Kared et al., 2013), and IL-21 is sufficient
to restore the in vitro proliferation of HCV-specific CD8+ T cells
(Kared et al., 2013; Radziewicz et al., 2007). In contrast, HCV-spe-
cific CD8+ T cells coexpress PD-1, Tim-3, CD160, and 2B4
(CD244) in chronic infection (Figure 2C; Bengsch et al., 2010;
Golden-Mason et al., 2007, 2009; Kroy et al., 2013; Nakamoto
et al., 2009; Radziewicz et al., 2007; Schlaphoff et al., 2011) and
combinedPD-1 andCTLA-4blockade is necessary to rescue their
in vitro function (Nakamoto et al., 2009).When PD-1 signaling was
blocked in vivo in three chimpanzees with chronic HCV, a signifi-
cantbut transient reduction inHCVviremiawasobserved in thean-
imal that had the strongest and broadest CD4+ and CD8+ T cell
response prior to development of chronic infection (Fuller et al.,
2013). It is therefore conceivable that inhibitory molecules such
as Tim-3 (McMahan et al., 2010) and additional factors, such as
increased numbers of Treg cells and inhibitory cytokines (e.g.,
IL-10 and TGF-b) also contribute to the impaired T cell responses
in chronic HCV infection (Franceschini et al., 2009; Golden-Mason
et al., 2007; Radziewicz et al., 2007; Timm et al., 2004).
Although downregulation of CD4+ and CD8+ T cell responses
against persistent antigenscanbe regardedasahostmechanism
to minimize liver disease, HCV also exhibits specific strategies to
escape from emerging cellular and humoral immune responses.
This is facilitated by its high replication rate and the lack of proof-
reading by its polymerase. The selection of nonsynonymous mu-
tations is highest in the acute phase of infection, and it is mostly
mediatedbyCD8+Tcells (Fuller et al., 2010). Amutation ina single
Tcell epitopeoften triggers the selectionof several compensatory
mutations to allow the virus to maintain its replicative fitness (Da-
zert et al., 2009). The effect of T cell selection pressure is illus-
trated by pregnancy-induced immune tolerance. The temporary
decrease in adaptive immune responses results in a temporary
reversion ofHCVescapemutationsand in an increase inHCV titer
that lasts until T cell selection pressure is reimposed after child-
birth (Honegger et al., 2013). A similar reversion of T cell escape
mutants is also observed upon transmission of HCV into individ-
uals that do not share the restricting HLA alleles with the source
(Timm et al., 2004). However, in the absence of such changes in
the infected host, HCV sequence evolution is predominantly
driven by the antibody responses in the chronic phaseof infection(C) Adaptive immune responses associated with differential outcome of acute H
critical factor for the outcome of acute HCV infection. In its presence, HCV-specifi
effector functions (top). In the absence or loss of a strong CD4+ T cell response,
antigen-specific stimulation. Those CD8+ T cells that target HCV escape variants
(see text for details). Treg indicates regulatory T cell.(Figure 2B) as a result of an increase in antibody breadth and titer
(von Hahn et al., 2007).
Comparative Aspects of Innate and Adaptive Immune
Responses in HAV, HBV, and HCV Infection
Because the acute phase of hepatitis C is clinically asymptom-
atic in most patients and HCV does not infect rodents, chimpan-
zees have been an important model to study the immune
response in the first few weeks after infection. The same model
has also been used in HAV and HBV infection to study intrahe-
patic immune responses early after infection.
Microarray analyses of prospectively collected chimpanzee
liver biopsies demonstrate an induction of ISGs within days of
HCV infection (Bigger et al., 2001; Su et al., 2002) along with a
plateau but not decrease in viral titer (Figures 2A and 2B). Despite
the early activation of innate interferon responses, it takes 8–
12 weeks until adaptive immune responses appear. In most
cases, these delayed HCV-specific T cell responses are weak
and narrowly focused and do not clear the infection (Shin et al.,
2013; Thimme et al., 2002). Likewise, neutralizing antibodies are
rarely detectable and isolate-specific in chimpanzees (Logvinoff
et al., 2004) and patients (Osburn et al., 2010; Pestka et al.,
2007). As described in the previous section of this review, the pri-
mary defect may be in the HCV-specific CD4+ T cell response.
Similar to HCV, HAV activates innate pattern recognition re-
ceptors in infected cells and cleaves downstream signaling mol-
ecules. The HAV dsRNA that is produced during its replication
cycle is sensed by TLR3, and a short peptide at the 50 end of
the HAV RNA is sensed by the cytoplasmic RIG-I-like receptor
melanoma differentiation associated gene 5 (Qu and Lemon,
2010). HAV also cleaves the adaptor molecules TRIF (Qu et al.,
2011) and MAVS (Yang et al., 2007) downstream of these sen-
sors. However, HAV is more successful in preventing innate im-
mune responses than HCV, considering that HAV induces only a
limited type I IFN response evenwith 100-fold higher intrahepatic
vital titers (Lanford et al., 2011). It therefore comes as a surprise
that HAV infection is self-limited rather than chronic. Viral clear-
ance coincides with a strong HAV-specific response by IFN-g-,
IL-2-, and IL-21-producing CD4+ T cells that appears 4–8 weeks
earlier than in HCV infection (Zhou et al., 2012) and, along with a
strong neutralizing antibody response, is associated with a
decline in HAV viremia and lifelong protective immunity.
Acute HBV infection is also cleared by a strong adaptive im-
mune response that confers lifelong protective immunity. Again,
this is inversely correlated to the innate response during the first
months of infection. HBV behaves as a stealth virus because
it does not induce an ISG response when it spreads through
the liver and infects almost 100% of the hepatocytes (Wieland
et al., 2004). Its invisibility to the innate immune response has
been attributed to its replication strategy. Replication occurs
within viral capsids in the cytoplasm, and the generated viral
RNAs are capped and polyadenylated, thereby resembling
host mRNAs (Wieland et al., 2004). However, the absence ofCV infection. A strong and maintained CD4+ T cell response appears to be a
c CD8+ T cell populations with an initially ‘‘stunned’’ phenotype acquire multiple
CD8+ T cells develop exhausted phenotypes, which are attributed to chronic
remain functional with a memory phenotype in the chronic phase of infection
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Figure 3. Conditions for T-Cell-Mediated Immune Protection upon
HCV Reinfection
(A) Clearance of a primary HCV infection is associated with strong T cell re-
sponses. A secondary HCV infection results in lower HCV titers andmore rapid
viral clearance. An early memory T cell recall response is detectable in both
liver and blood.
(B) Depletion of CD4+ T cells in chimpanzees prior to secondary HCV infection
results in weak recall responses, incomplete T-cell-mediated control of
viremia, and emergence of MHC class I escape mutations. Chronic infection
ensues.
(C) T cell responses that are induced by repeated exposure to trace amounts of
HCV, in the absence of quantifiable systemic viremia and seroconversion
(‘‘subinfectious HCV exposure’’), do not confer immune protection upon HCV
reinfection. The absence of immune protection is associated with an expan-
sion of Treg cells during subinfectious HCV exposure and subsequent HCV
challenge. The intensity of the shaded background indicates the degree of
intrahepatic inflammation in the different phases of hepatitis.
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HBV-specific CD4+ T cell response, which appears much earlier
than in HCV infection (Asabe et al., 2009). This CD4+ T cell
response determines the outcome of HBV infection because
CD4+ T cell depletion in the chimpanzee model abrogates the
antiviral CD8+ T cell response and results in chronic infection
(Asabe et al., 2009).
Collectively, these observations raise the interesting hypothe-
sis that the absence rather than presence of a strong type I IFN
response is critical for the induction of a successful CD4+ T cell
response. This is consistent with data in LCMV-infected mice in20 Immunity 40, January 16, 2014 ª2014 Elsevier Inc.which blockade of type I IFN signaling increases the frequency
and function of virus-specific CD4+ T cells (Teijaro et al., 2013;
Wilson et al., 2013).
Conditions for Induction and Maintenance of Protective
Immunity
Most vaccines, including those against HAV and HBV, induce an
antibody response that is also observed in subjects with natural
immunity. However, in contrast to the strong humoral immune
responses in acute self-limited HAV and HBV infection, broadly
neutralizing antibodies against HCV are generated only after
months to years of chronic infection (Logvinoff et al., 2004).
The recent resolution of the HCV E2 envelope core structure
(Kong et al., 2013) may help to identify conserved structural
determinants that are recognized by such broadly neutralizing
antibodies and facilitate the design of immunogens to induce
them. Additionally, an ideal HCV vaccine would induce T cell
responses that are similar to those of patients who recover spon-
taneously from the infection. What is the evidence that such
T cell responses are protective upon reinfection?
A small population of HCV-specific memory T cells persists for
decades after spontaneous HCV clearance and can readily be
expanded from the blood by in vitro stimulation with HCV anti-
gens (Takaki et al., 2000). These cells protect HCV-recovered
chimpanzees from developing chronic infection upon heterolo-
gous and cross-genotype HCV rechallenge as evidenced by
lower amounts of viremia and faster clearance than in a primary
infection and lack of liver disease (Figure 3A; Lanford et al., 2004;
Nascimbeni et al., 2003). Depletion of either CD4+ or CD8+ T cells
prior to rechallenge of these chimpanzees abrogates this protec-
tive but not sterilizing immunity (Figure 3B; Grakoui et al., 2003;
Shoukry et al., 2003). In contrast to such controlled studies on
primary and secondary infections in chimpanzees, prospective
studies in humans underestimate the rate of T cell-based protec-
tion because they miss episodes of reinfection and clearance re-
sulting from the short duration of viremia and the lack of clinical
symptoms. However, it has been reported that clearance of a pri-
mary infection results in a greatly reduced chance of developing
chronic hepatitis C in subsequent infections (Mehta et al., 2002;
Osburn et al., 2010). This protection is lost upon infection with
HIV and reduction of CD4+ T cell counts, thus supporting a role
of CD4+ T cells (Mehta et al., 2002).
The conditions that result in such protective T cell responses
need to be further defined. HCV-specific T cell responses are de-
tected in some subjects without history of acute HCV infection
despite frequent exposure (Mizukoshi et al., 2008; Thurairajah
et al., 2008). Such T cells can indeed be induced in the absence
of systemic viremia and seroconversion by repeated exposure to
trace amounts of HCV as demonstrated in health care workers
after accidental needlestick injury (Heller et al., 2013) and in the
chimpanzee model (Park et al., 2013). However, such T cell
responses do not protect chimpanzees upon subsequent
challenge with HCV. Rather, HCV-specific recall and de novo
responses, as well as intrahepatic T cell recruitment and IFN-g
production, are suppressed. This is associated with an increase
in Treg cell frequency during subinfectious HCV exposure and
subsequent HCV challenge (Figure 3C; Park et al., 2013). Thus,
repeated low-dose exposure, as observed in endemic areas or
in injection drug users, may not confer protective immunity but
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Reviewinstead expand Treg cells and suppress immune responses dur-
ing subsequent acute infection. In addition, it should be noted
that even proven protective immunity can be lost, e.g., by multi-
ple sequential high-dose heterologous HCV challenges of a
spontaneously recovered chimpanzee (Bukh et al., 2008).
Our current understanding that strong T cell-mediated immu-
nity is crucial for protection against chronic HCV infection has
informed vaccine studies. Vaccination with an adenovirus prime,
DNA boost regimen induces strong HCV-specific T cell re-
sponses against HCV nonstructural antigens in chimpanzees,
which develop a significantly shorter duration of viremia and
lower HCV titer than do mock-vaccinated control chimpanzees
upon subsequent HCV challenge (Folgori et al., 2006). Further-
more, alanine amino transferase (ALT) levels do not increase.
Key to this protective immunity is the induction and early expan-
sion of HCV-specific T cells with a high degree of functionality
and high expression of the memory precursor marker CD127
(Park et al., 2012b). This is reminiscent of the early expansion
of CD127+ HCV-specific T cells with high functionality in chim-
panzees that proceed to clear acute HCV infection (Shin et al.,
2013). A similar approach induces multispecific and multifunc-
tional HCV-specific CD4+ and CD8+ T cell responses in healthy
subjects for at least a year after vaccination (Barnes et al., 2012).
Additional cues for the maintenance of strong immune
responses may come from HBV infection. In contrast to HCV and
HAV, HBV is not necessarily cleared completely in subjects who
recover from acute infection. Rather, trace amounts of HBV DNA
appear sporadically in the circulation (Rehermann et al., 1996)
and cccDNAcanpersist in the formof aminichromosome (Levrero
etal., 2009).These traceamountsofsporadically reappearingvirus
sustainHBV-specifichumoral andcellular immune responses, and
vice versa are controlled by them (Hoofnagle, 2009). This scenario
is mimicked by the use of persistent CMV-derived vectors to
deliver vaccine antigens. Although not yet tested in anHCVmodel,
such vectors established indefinitely persistent, high-frequency,
effector memory T cells in macaques vaccinated against simian
immunodeficiencyvirus (SIV) andprotect theanimalsuponahighly
pathogenic SIV challenge (Hansen et al., 2011, 2013).
Concluding Remarks and Areas for Future Research
In the past 60 years, great progress has been made in under-
standing and treating viral hepatitis. This includes the molecular
cloning of the parenterally transmitted HCV, HBV, and HDV
and the enterally transmitted HAV and HEV, the development
of protective vaccines against HAV, HBV, and HEV, the use of
IFN-based therapies for all chronic hepatitis virus infections,
and the design of antiviral agents that suppress HBV replication
and clear HCV. For HCV, one of the most recently discovered
hepatitis viruses, a detailed picture of its interaction with host
innate and adaptive immune responses has emerged. These
includemechanisms of inducing and evading strong innate inter-
feron-based responses. Chronic innate immune activation,
together with host genetic factors, negatively predict HCV clear-
ance in response to IFN-based therapy. Although HCV persists
in most infected individuals, successful adaptive immune re-
sponses were defined that not only clear a primary infection
but also protect upon a secondary infection. The area that re-
quires the greatest immunological effort is the development of
an HCV vaccine. Apart from developing methods to induce pro-tective memory T cell responses, this should include the charac-
terization and induction of broadly neutralizing antibody re-
sponses. For HAV and HEV, a better understanding of the
factors that drive the severe immunopathogenesis of fulminant
hepatitis is necessary. Likewise, the immunopathogenesis of
HDV infection, a virus that causes severe liver disease upon
co- and superinfection with HBV, has not been characterized.
With regards to HBV, a better understanding is needed of the
factors that drive the onset of immuno-active disease in those in-
dividuals who are infected early in life. Because antivirals sup-
press but do not clear HBV infection, much remains to be done
for those individuals who are already chronically infected and
at risk of developing liver cirrhosis and hepatocellular carcinoma.
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